Skip to content

Virological and immunological assessment in HIV positive participants on 2DR versus 3DR in a prospective randomized controlled switch trial.

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-515265-34-00
Acronym
2DR-study (Rumba)
Enrollment
134
Registered
2024-10-09
Start date
2020-05-26
Completion date
Unknown
Last updated
2024-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

human immunodeficiency viruses (HIV)

Brief summary

The primary endpoint is the amount of intact replication competent HIV sequences at W48 quantified by the fraction intact HIV viral sequences quantified by an intact proviral DNA assay, present in blood CD4 cells.

Detailed description

Quantification of viral markers as total and intact HIV DNA, and RNA transcripts at baseline, W48, W144 and W240., Full length sequencing of the virus at baseline, W144 and W240., Quantification of human pro-inflammatory mediators and markers of microbial translocation at baseline, W48, W144 and W240., Phenotype of innate immune cells at baseline W48, W144, W240., Function of immune cells at baseline,W144 and W240., Metabolic parameters at baseline, W24, W48, W72, W96, W120,W144, W186, W192, W216 and W240., Analysis of cardio-vascular risk at W240 based on risk stratification at D0, W48 and W144 in all or a subgroup of individuals.

Interventions

Sponsors

Universitair Ziekenhuis Gent, Universitair Ziekenhuis Gent
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
The primary endpoint is the amount of intact replication competent HIV sequences at W48 quantified by the fraction intact HIV viral sequences quantified by an intact proviral DNA assay, present in blood CD4 cells.

Secondary

MeasureTime frame
Quantification of viral markers as total and intact HIV DNA, and RNA transcripts at baseline, W48, W144 and W240., Full length sequencing of the virus at baseline, W144 and W240., Quantification of human pro-inflammatory mediators and markers of microbial translocation at baseline, W48, W144 and W240., Phenotype of innate immune cells at baseline W48, W144, W240., Function of immune cells at baseline,W144 and W240., Metabolic parameters at baseline, W24, W48, W72, W96, W120,W144, W186, W192, W216 and W240., Analysis of cardio-vascular risk at W240 based on risk stratification at D0, W48 and W144 in all or a subgroup of individuals.

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026